FibroBiologics, Inc.
FBLG
$0.95
$0.022.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -143.64% | -67.06% | -4.06% | 32.09% | 65.97% |
| Total Depreciation and Amortization | 52.09% | 45.20% | 36.55% | 27.75% | 24.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 182.93% | 319.39% | -45.50% | -107.80% | -136.08% |
| Change in Net Operating Assets | -41.20% | -692.49% | -295.07% | -238.32% | -220.94% |
| Cash from Operations | -20.01% | -37.75% | -56.33% | -66.68% | -49.32% |
| Capital Expenditure | 0.00% | -42.39% | -314.94% | 25.15% | 51.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -42.39% | -314.94% | 25.15% | 51.01% |
| Total Debt Issued | -49.98% | -56.14% | 2,299.83% | 2,299.83% | 1,537.63% |
| Total Debt Repaid | -658.39% | -492.33% | 74.95% | 0.00% | -299.13% |
| Issuance of Common Stock | 55.63% | -12.22% | -99.40% | 66.30% | 66.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -37.51% | -55.26% | 80.88% | 349.23% | 444.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,511.59% | -288.53% | -0.71% | 153.14% | 107.73% |